HUE055621T2 - Il-33-ellenes antitestek és alkalmazásaik - Google Patents

Il-33-ellenes antitestek és alkalmazásaik

Info

Publication number
HUE055621T2
HUE055621T2 HUE17794593A HUE17794593A HUE055621T2 HU E055621 T2 HUE055621 T2 HU E055621T2 HU E17794593 A HUE17794593 A HU E17794593A HU E17794593 A HUE17794593 A HU E17794593A HU E055621 T2 HUE055621 T2 HU E055621T2
Authority
HU
Hungary
Prior art keywords
antibodies
Prior art date
Application number
HUE17794593A
Other languages
English (en)
Inventor
Robert Jan Benschop
Julian Davies
Angela Jeannine Okragly
Chetankumar Natvarlal Patel
Stephanie Marie Truhlar
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HUE055621T2 publication Critical patent/HUE055621T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HUE17794593A 2016-10-28 2017-10-24 Il-33-ellenes antitestek és alkalmazásaik HUE055621T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662414258P 2016-10-28 2016-10-28

Publications (1)

Publication Number Publication Date
HUE055621T2 true HUE055621T2 (hu) 2021-12-28

Family

ID=60263117

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17794593A HUE055621T2 (hu) 2016-10-28 2017-10-24 Il-33-ellenes antitestek és alkalmazásaik

Country Status (36)

Country Link
US (2) US10501536B2 (hu)
EP (1) EP3532499B1 (hu)
JP (1) JP6830533B2 (hu)
KR (1) KR102266144B1 (hu)
CN (1) CN109863173B (hu)
AR (1) AR109948A1 (hu)
AU (1) AU2017351183B2 (hu)
BR (1) BR112019005139A2 (hu)
CA (1) CA3039232C (hu)
CL (1) CL2019001043A1 (hu)
CO (1) CO2019003047A2 (hu)
CR (1) CR20190179A (hu)
CY (1) CY1124360T1 (hu)
DK (1) DK3532499T3 (hu)
EA (1) EA201990778A1 (hu)
EC (1) ECSP19029758A (hu)
ES (1) ES2878037T3 (hu)
HR (1) HRP20211221T1 (hu)
HU (1) HUE055621T2 (hu)
IL (1) IL265689B2 (hu)
JO (1) JOP20190093A1 (hu)
LT (1) LT3532499T (hu)
MA (1) MA46619B1 (hu)
MD (1) MD3532499T2 (hu)
MX (1) MX2019004863A (hu)
PE (1) PE20191045A1 (hu)
PH (1) PH12019500929A1 (hu)
PL (1) PL3532499T3 (hu)
PT (1) PT3532499T (hu)
RS (1) RS62120B1 (hu)
SI (1) SI3532499T1 (hu)
TN (1) TN2019000086A1 (hu)
TW (2) TWI676680B (hu)
UA (1) UA121293C2 (hu)
WO (1) WO2018081075A1 (hu)
ZA (1) ZA201901935B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190093A1 (ar) * 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
JP2022552323A (ja) 2019-10-15 2022-12-15 イーライ リリー アンド カンパニー 組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株
TW202134261A (zh) 2019-11-04 2021-09-16 英商梅迪繆思有限公司 使用il-33拮抗劑之方法
JP2023501316A (ja) 2019-11-04 2023-01-18 メドイミューン・リミテッド 腎機能障害を治療するための抗ｉｌ－３３治療薬
US20230110203A1 (en) 2020-03-13 2023-04-13 Medimmune Limited Therapeutic methods for the treatment of subjects with risk alelles in il33
JP2023517345A (ja) 2020-03-13 2023-04-25 ジェネンテック， インコーポレイテッド 抗インターロイキン－３３抗体及びその使用
CA3176571A1 (en) 2020-04-06 2021-10-14 Medimmune Limited Treating acute respiratory distress syndrome with il-33 axis binding antagonists
CA3181765A1 (en) 2020-05-11 2021-11-18 Medimmune Limited Formulations of anti-il-33 antibodies
CN111620948B (zh) * 2020-06-10 2022-04-08 南京赛新生物科技有限公司 针对il-33的抗体
CN113603775B (zh) * 2021-09-03 2022-05-20 江苏荃信生物医药股份有限公司 抗人白介素-33单克隆抗体及其应用
TW202402790A (zh) 2022-03-25 2024-01-16 英商梅迪繆思有限公司 減少呼吸系統感染之方法
WO2024038185A1 (en) 2022-08-19 2024-02-22 Medimmune Limited Method of selecting patients for treatment with an il-33 axis antagonist

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
WO2008132709A1 (en) 2007-04-26 2008-11-06 Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Products for altering il-33 activity and methods therefor
CA2686683A1 (en) 2007-05-18 2008-11-27 Medimmune, Llc Il-33 in inflammatory disease
WO2011031600A1 (en) * 2009-09-10 2011-03-17 Schering Corporation Use of il-33 antagonists to treat fibrotic disease
MX341958B (es) * 2011-02-23 2016-09-08 Hoffmann La Roche Anticuerpos contra el il33r humano y usos de los mismos.
FR2972006B1 (fr) 2011-02-24 2016-03-25 Centre Nat Rech Scient Nouveaux fragments d'il-33 superactifs et leurs utilisations
US9090694B2 (en) 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
JO3532B1 (ar) * 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
BR112016013347B1 (pt) 2013-12-26 2023-12-12 Mitsubishi Tanabe Pharma Corporation Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos
AU2015204674B2 (en) * 2014-01-10 2020-09-03 Anaptysbio, Inc. Antibodies directed against interleukin-33 (IL-33)
US10040859B2 (en) * 2014-04-21 2018-08-07 The Children's Hospital Of Philadelphia Methods of treating hemophagocytic lymphohistiocytosis with an IL-33 receptor antibody
EA201791029A1 (ru) 2014-11-10 2017-12-29 Дженентек, Инк. Антитела против интерлейкина-33 и их применение
EP3733701A1 (en) 2015-03-31 2020-11-04 MedImmune Limited A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
EP3402521A4 (en) 2016-01-14 2019-11-20 AnaptysBio, Inc. INHIBITION OF ALLERGIC REACTION USING AN IL-33 INHIBITOR
JOP20190093A1 (ar) * 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها

Also Published As

Publication number Publication date
BR112019005139A2 (pt) 2019-06-04
SI3532499T1 (sl) 2021-08-31
US20180118821A1 (en) 2018-05-03
HRP20211221T1 (hr) 2021-10-29
US10913793B2 (en) 2021-02-09
WO2018081075A1 (en) 2018-05-03
MX2019004863A (es) 2019-08-12
US10501536B2 (en) 2019-12-10
CA3039232A1 (en) 2018-05-03
AR109948A1 (es) 2019-02-06
DK3532499T3 (da) 2021-06-28
MA46619B1 (fr) 2021-09-30
US20200048340A1 (en) 2020-02-13
TW201920675A (zh) 2019-06-01
CO2019003047A2 (es) 2019-04-12
ECSP19029758A (es) 2019-05-31
TN2019000086A1 (en) 2020-07-15
CR20190179A (es) 2019-08-26
EA201990778A1 (ru) 2019-09-30
IL265689B2 (en) 2024-02-01
UA121293C2 (uk) 2020-04-27
KR102266144B1 (ko) 2021-06-18
CN109863173A (zh) 2019-06-07
JOP20190093A1 (ar) 2019-04-25
CL2019001043A1 (es) 2019-08-30
CA3039232C (en) 2021-05-25
JP6830533B2 (ja) 2021-02-17
AU2017351183A1 (en) 2019-04-11
TW201829459A (zh) 2018-08-16
RS62120B1 (sr) 2021-08-31
KR20190054160A (ko) 2019-05-21
EP3532499A1 (en) 2019-09-04
AU2017351183B2 (en) 2020-04-09
ZA201901935B (en) 2020-11-25
ES2878037T3 (es) 2021-11-18
EP3532499B1 (en) 2021-05-05
CY1124360T1 (el) 2022-07-22
LT3532499T (lt) 2021-08-10
JP2019534282A (ja) 2019-11-28
PT3532499T (pt) 2021-07-05
TWI676680B (zh) 2019-11-11
PL3532499T3 (pl) 2021-11-08
IL265689A (en) 2019-05-30
PH12019500929A1 (en) 2019-12-02
TWI647238B (zh) 2019-01-11
MD3532499T2 (ro) 2021-09-30
PE20191045A1 (es) 2019-08-06
CN109863173B (zh) 2022-06-03
IL265689B1 (en) 2023-10-01

Similar Documents

Publication Publication Date Title
IL283321A (en) Antibodies against muc16 and their uses
IL285375A (en) Antibodies that bind to il-8 and their uses
IL267942B (en) Anti-cd73 antibodies and uses thereof
HK1254861A1 (zh) 抗lag3抗體及其用途
IL266738A (en) Novel antibodies and their uses
IL262095A (en) Anti-pacap antibodies and their use
HK1250238A1 (zh) 抗angptl8抗體及其用途
SG10201912199XA (en) Anti-tim-3 antibodies and use thereof
IL268734A (en) Anti-LAG-3 antibodies and uses thereof
IL268700A (en) Anti-PHF-tau antibodies and uses thereof
HK1256381A1 (zh) 抗pacap抗體及其用途
EP3541840C0 (en) ANTI-HLA-G ANTIBODIES AND THEIR USE
ZA201901935B (en) Anti-il-33 antibodies and uses thereof
GB201503387D0 (en) Anti-carbapenem antibodies and uses thereof
RS62912B1 (sr) Antihumana-her3 antitela i njihova primena
IL266049A (en) Antibodies against o1 and their uses
IL266082A (en) Anti-chikv antibodies and their use
IL264417A (en) Anti-o2 antibodies and their uses
GB201712032D0 (en) Antibodies and uses thereof
HK1254240A1 (zh) 抗羥腐胺賴氨酸抗體及其用途